-
Your Trusted Generics Medicine Supplier
- +91 84484 44095 / 8071 555 357
-
Mumbai, India
Eng
简体中文
العربيّة
Healthcare Professional Resources
Comprehensive clinical information and resources for healthcare professionals prescribing Mefloquin® Tablets USP 250mg.
Professional Use Only
This section contains information intended for healthcare professionals. This information is not intended for use by patients or consumers.
Clinical Study References
Efficacy Studies
Randomized Controlled Trials
Multiple double-blind, randomized controlled trials demonstrating efficacy of mefloquine in treatment of uncomplicated P. falciparum malaria.
- Cure rates: 95-98% in susceptible strains
- Comparison studies vs. other antimalarials
- Multicenter trials across endemic regions
Key Publications: Lancet, NEJM, BMJ, Tropical Medicine & International Health
Safety Studies
Post-Marketing Surveillance
Comprehensive safety data from post-marketing surveillance and pharmacovigilance programs.
- Adverse event profile analysis
- Psychiatric side effect monitoring
- Long-term safety data
- Special population safety studies
Data Sources: WHO Pharmacovigilance, FDA Adverse Event Reporting System
Special Population Studies
Pediatric & Geriatric Studies
Dedicated studies in special populations including children, elderly, and pregnant women.
- Pediatric dosing optimization studies
- Pregnancy safety registry data
- Elderly pharmacokinetic studies
- Renal/hepatic impairment studies
Clinical Trial Registries: ClinicalTrials.gov, EU Clinical Trials Register
Treatment Guidelines
WHO Guidelines
World Health Organization Malaria Treatment Guidelines:
- Recommended for treatment of uncomplicated P. falciparum malaria
- Alternative first-line treatment in areas with chloroquine resistance
- Recommended for prophylaxis in specific high-risk areas
- Dosing guidelines for adults and children
Latest Update: WHO Guidelines for the Treatment of Malaria (3rd edition, 2023)
CDC Guidelines
CDC Health Information for International Travel:
- Recommended for prophylaxis in specific regions
- Contraindications and precautions
- Alternative regimens when mefloquine contraindicated
- Pre-travel counseling recommendations
Latest Update: CDC Yellow Book 2024
National Guidelines
Country-Specific Treatment Guidelines:
- India National Vector Borne Disease Control Program
- UK Public Health England Guidelines
- Australia Therapeutic Guidelines
- Canada Public Health Agency Guidelines
Resistance Information
Global Resistance Patterns
High Resistance Areas
- Thai-Myanmar and Thai-Cambodia borders
- Western Cambodia
- Eastern Myanmar
- Southern Vietnam
Recommendation: Avoid use, consider alternatives
Moderate Resistance Areas
- Parts of Africa (emerging resistance)
- South America (Amazon region)
- Some Pacific islands
Recommendation: Use with local resistance data
Low Resistance Areas
- Most of Sub-Saharan Africa
- Caribbean
- Central America
Recommendation: Mefloquine remains effective
Resistance Monitoring
Continuous monitoring of mefloquine resistance through:
- In vivo therapeutic efficacy studies
- Molecular marker surveillance
- In vitro susceptibility testing
- Pharmacovigilance for treatment failures
Prescribing Information
Complete Prescribing Information
Comprehensive prescribing information including:
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Use in Specific Populations
- Overdosage
- How Supplied/Storage and Handling
- Patient Counseling Information
Dosing Calculators
Pediatric Dosing Calculator
Weight-based dosing calculator for children 6 months to 16 years:
- Treatment: 25mg/kg (max 1250mg)
- Prophylaxis: 5mg/kg (max 250mg)
Note: Always verify dosing with current guidelines
Renal/Hepatic Impairment Dosing
Special dosing considerations for patients with organ impairment:
- Renal impairment: No dose adjustment needed
- Hepatic impairment: Use with caution, avoid if severe
- Elderly: Standard adult dose with monitoring
FAQ for Doctors
When should mefloquine be avoided?
Avoid in patients with: history of seizures, psychiatric disorders, cardiac conduction abnormalities, or known hypersensitivity. Also avoid in first trimester of pregnancy.
What are the most common psychiatric side effects?
Anxiety, depression, sleep disturbances, unusual dreams, and in rare cases, psychosis or suicidal ideation. Monitor patients closely, especially during first few weeks.
How long do side effects last after discontinuation?
Most side effects resolve within weeks, but psychiatric symptoms can persist for months in rare cases. Long half-life (2-3 weeks) contributes to prolonged effects.
Can mefloquine be used in combination with other antimalarials?
Generally not recommended due to increased cardiac toxicity. Avoid with halofantrine, quinine, and quinidine. Consult current guidelines for specific combinations.
What monitoring is required during treatment?
Monitor for psychiatric symptoms, cardiac effects in high-risk patients, and liver function in prolonged use. Patient education about side effects is crucial.